# European Journal of Cancer

Source: https://onco.cc/journals/european-journal-of-cancer/  
OnCo record `european-journal-of-cancer` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The European Journal of Cancer is the Elsevier journal affiliated with the European Organisation for Research and Treatment of Cancer, publishing phase 2 and 3 trials, EORTC quality-of-life questionnaire work, European guidelines on melanoma and skin cancers, and EUROCARE registry epidemiology. It is the place to look for European trial reports and consensus statements.

## Summary

The European Journal of Cancer (Eur J Cancer, EJC) is the European journal for clinical and translational cancer research affiliated with the European Organisation for Research and Treatment of Cancer (EORTC), founded in 1965 and published by Elsevier on a hybrid access model. It publishes phase 2 and 3 trials, EORTC quality-of-life questionnaire development and validation, European interdisciplinary guidelines (for example on melanoma and skin cancers), and registry-based epidemiology from EUROCARE. Its readers are clinical and translational oncologists, and it is notable for melanoma, sarcoma, quality-of-life and European guideline work. Within OnCo it is cited from the Desmoid tumour entry, and it is the place to look for European trial reports and guideline consensus.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: Eur J Cancer; EJC
- Publisher: Elsevier
- Scope: clinical oncology
- Access: hybrid

## Sources

- EORTC: https://www.eortc.org

## Connected records

- collections: [PubMed & Europe PMC](https://onco.cc/collections/pubmed-europepmc/)
- terms: [Preclinical](https://onco.cc/terms/preclinical/), [Quality of life and patient-reported outcomes (QoL, PRO)](https://onco.cc/terms/qol-pro/)
- people: [Claudio Lombardo](https://onco.cc/people/claudio-lombardo/), [Roman Rouzier](https://onco.cc/people/roman-rouzier/), [Sandra Nolte](https://onco.cc/people/sandra-nolte/), [Vasanta Nanduri](https://onco.cc/people/vasanta-nanduri/)
- key papers: [A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report](https://onco.cc/key-papers/paper-carboplatin-glioblastoma-eur-j-cancer-2017/), [A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours](https://onco.cc/key-papers/paper-nct05751798-eur-j-cancer-2026/), [Active surveillance in desmoid-type fibromatosis: A systematic literature review](https://onco.cc/key-papers/paper-timbergen-eur-j-cancer/), [Bien 2011: pancreatoblastoma, a report from the European cooperative study group for paediatric rare tumours (EXPeRT)](https://onco.cc/key-papers/paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011/), [DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer](https://onco.cc/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/), [EGFR and cancer prognosis](https://onco.cc/key-papers/paper-egfr-gastric-eur-j-cancer-2001/), [Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)](https://onco.cc/key-papers/paper-clover-eur-j-cancer/), [First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study](https://onco.cc/key-papers/paper-nct04657991-eur-j-cancer-2024/), [Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial](https://onco.cc/key-papers/paper-nct05732805-eur-j-cancer-2025/), [MIRACULUM: prolgolimab, the first Russian-developed anti-PD-1 antibody, in advanced melanoma](https://onco.cc/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/), [Rare cancers are not so rare: the rare cancer burden in Europe](https://onco.cc/key-papers/paper-gatta-eur-j-cancer/), [Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)](https://onco.cc/key-papers/paper-peter-thuss-patience-eur-j-cancer-2011/)
- cancers: [Desmoid tumour](https://onco.cc/cancers/desmoid-tumour/)

---
JSON: https://onco.cc/api/v1/entities/european-journal-of-cancer.json